This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AMC FUD Runneth Over: Panic at the Casino!
by Kevin Cook
Should AMC be worth over 5X what Amazon just paid for MGM Studios?
CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.
Why Is Editas (EDIT) Down 2.9% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -13.16% and 2.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
Editas (EDIT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.
Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership
by Zacks Equity Research
Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.
Why Is Editas (EDIT) Down 9.6% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Software is the New Gold: Storing Value in the Digital-Crypto Age
by Kevin Cook
Time for the final nail in the gilded sarcophagus of the barbarous relic.
bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study
by Zacks Equity Research
bluebird (BLUE) gains following the updated findings from the reported case of AML in LentiGlobin for SCD gene therapy program.
Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.
Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed the most recent trading day at $57.94, moving +1.35% from the previous trading session.
GameStop Lessons: Becoming a Savvy Investor with ETFs
by Kevin Cook
As more young investors take up day trading, I have a recipe for long-term wealth creation
Bear of the Day: CRISPR Therapeutics (CRSP)
by Kevin Cook
Gene editors got a big boost recently from sickle cell potential and Cathie Wood's thematic investing
5 Best ETFs for Young Investors
by Kevin Cook
As more young investors take up day trading, I have an important recipe for long-term wealth creation.
Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $63.18, marking a +1.64% move from the previous day.
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $65.47, marking a -0.44% move from the previous day.
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Maker of premier next-gen genomic sequencing technology lowers guidance but shares make new highs
CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.
Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why
by Zacks Equity Research
Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.
Editas Medicine (EDIT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed at $76.14 in the latest trading session, marking a +0.29% move from the prior day.
Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301
by Zacks Equity Research
The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.